These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 6680757

  • 1. Potentiation of antitumor immunity in tumor-bearing mice by a degraded D-manno-D-glucan (DMG), a new antitumor polysaccharide.
    Nakajima H, Kita Y, Hashimoto S, Tsukada W, Abe S, Mizuno D.
    Jpn J Exp Med; 1983 Dec; 53(6):281-8. PubMed ID: 6680757
    [Abstract] [Full Text] [Related]

  • 2. Combination therapy of murine tumors with a degraded D-manno-D-glucan (DMG) from Microellobosporia grisea, and cyclophosphamide.
    Nakajima H, Hashimoto S, Kita Y, Takashi T, Tsukada W, Kohno M, Ogawa H, Abe S, Mizuno D.
    Jpn J Exp Med; 1983 Dec; 53(6):263-9. PubMed ID: 6240552
    [Abstract] [Full Text] [Related]

  • 3. Immunopotentiation by a new antitumor polysaccharide, DMG, a degraded D-manno-D-glucan from Microellobosporia grisea culture fluid.
    Nakajima H, Kita Y, Takashi T, Akasaki M, Yamaguchi F, Ozawa S, Tsukada W, Abe S, Mizuno D.
    Gan; 1984 Mar; 75(3):260-8. PubMed ID: 6427053
    [Abstract] [Full Text] [Related]

  • 4. Host-mediated antitumor effect of DMG, a degraded D-manno-D-glucan from Microellobosporia grisea culture fluid.
    Nakajima H, Hashimoto S, Nagao S, Kita Y, Khono M, Ogawa H, Abe S, Mizuno D.
    Gan; 1984 Mar; 75(3):253-9. PubMed ID: 6233200
    [Abstract] [Full Text] [Related]

  • 5. Changes of antitumor immunity of hosts with murine mammary tumors regressed by lentinan: potentiation of antitumor delayed hypersensitivity reaction.
    Masuko Y, Nakajima H, Tsubouchi J, Yamazaki M, Mizuno D, Abe S.
    Gan; 1982 Oct; 73(5):790-7. PubMed ID: 7166231
    [Abstract] [Full Text] [Related]

  • 6. Antitumor effect of actinomycin D entrapped in liposomes bearing subunits of tumor-specific monoclonal immunoglobulin M antibody.
    Hashimoto Y, Sugawara M, Masuko T, Hojo H.
    Cancer Res; 1983 Nov; 43(11):5328-34. PubMed ID: 6616468
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Maitake D-Fraction enhances antitumor effects and reduces immunosuppression by mitomycin-C in tumor-bearing mice.
    Kodama N, Murata Y, Asakawa A, Inui A, Hayashi M, Sakai N, Nanba H.
    Nutrition; 2005 May; 21(5):624-9. PubMed ID: 15850970
    [Abstract] [Full Text] [Related]

  • 10. [Preparation and anti-tumor activity of monoclonal antibody against ascitic mammary tumor MM46 cells].
    Takahashi T, Seto M, Hara T.
    Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):544-50. PubMed ID: 6192760
    [Abstract] [Full Text] [Related]

  • 11. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
    Harada M, Matsuzaki G, Yoshikai Y, Kobayashi N, Kurosawa S, Takimoto H, Nomoto K.
    Cancer Res; 1993 Jan 01; 53(1):106-11. PubMed ID: 8093229
    [Abstract] [Full Text] [Related]

  • 12. Augmentation of specific cell-mediated immune responses to tumor cells in tumor-bearing rats pretreated wih the antileukemia drug busulfan.
    Mizushima Y, Sendo F, Miyake T, Kobayashi H.
    J Natl Cancer Inst; 1981 Apr 01; 66(4):659-65. PubMed ID: 6939913
    [Abstract] [Full Text] [Related]

  • 13. Elimination of tumor-enhancing cells by cyclophosphamide and its relevance to cyclophosphamide therapy of the murine mammary tumor.
    Nakajima H, Abe S, Masuko Y, Tsubouchi J, Yamazaki M, Mizuno D.
    Gan; 1981 Oct 01; 72(5):723-31. PubMed ID: 7327373
    [Abstract] [Full Text] [Related]

  • 14. Evidence for cytostatic T cell activity in the effector mechanism against syngeneic TMT mammary tumor cells in mice.
    Kurata S, Tsuchiya T, Norimura T, Yamashita U.
    J Immunol; 1983 Jan 01; 130(1):496-500. PubMed ID: 6600195
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Immunologic factors influencing the intra-tumor localization of ADCC effector cells.
    Haskill S, Parthenais E.
    J Immunol; 1978 Jun 01; 120(6):1813-7. PubMed ID: 659877
    [Abstract] [Full Text] [Related]

  • 18. Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression.
    Kurzawa H, Wysocka M, Aruga E, Chang AE, Trinchieri G, Lee WM.
    Cancer Res; 1998 Feb 01; 58(3):491-9. PubMed ID: 9458095
    [Abstract] [Full Text] [Related]

  • 19. [Enhancement of antitumor immune responses by bleomycin].
    Morikawa K.
    Hokkaido Igaku Zasshi; 1988 Sep 01; 63(5):772-80. PubMed ID: 2467868
    [Abstract] [Full Text] [Related]

  • 20. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
    Merritt RE, Yamada RE, Crystal RG, Korst RJ.
    J Thorac Cardiovasc Surg; 2004 Feb 01; 127(2):355-64. PubMed ID: 14762342
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.